logo-loader
viewXphyto Therapeutics Corp.

XPhyto Therapeutics subsidiary, Bunker granted license for cannabis cultivation and extraction licence for scientific purposes in Germany

XPhyto said the licence is valid and authorizes the company to cultivate and extract up to 70 different strains of Cannabis sativa and indica at Bunker’s high-security facility in Bavaria

Cannabis cultivation
Hugh Rogers, XPhyto’s CEO commented: “XPhyto’s German cannabis cultivation and extraction licence is a unique opportunity for our European operations"

XPhyto Therapeutics Corp. revealed that the German Federal Institute for Drugs and Medical Devices (BfArM) has granted the privately-held firm’s wholly owned German subsidiary, Bunker Pflanzenextrakte GmbH, a cannabis cultivation and extraction licence for scientific purposes.

In a statement, XPhyto said that, subject to meeting BfArM security requirements, the licence is valid and authorizes the company to cultivate and extract up to 70 different strains of Cannabis sativa and indica for scientific purposes at Bunker’s high-security facility located in a monitored security area in Bavaria, in the south of Germany.

Hugh Rogers, XPhyto’s CEO commented: “XPhyto’s German cannabis cultivation and extraction licence is a unique opportunity for our European operations. With a focus on Canada and Germany, we are building an industry leading medical cannabis company focused on pharmaceutical-grade quality and scientific validation.”

Robert Barth, VP European Corporate Development of XPhyto and Managing Director of Bunker added: “Germany is emerging as the largest legal medical cannabis market in the world and we expect it to grow to be a multi-billion dollar industry within five years. XPhyto is well positioned as a first-mover in this exciting market,”

XPhyto, which is a science-focused cannabis company developing analytical testing, processing, and formulation capability in Canada and research, cultivation, extraction, import, distribution, and manufacturing in Germany, has filed a final prospectus with the British Columbia Securities Commission and has applied to list on the Canadian Securities Exchange (CSE).

Subject to final listing approval, the company expects to trade on the CSE in the next 30 days and has reserved the trading symbol ‘XPHY’.

The firm has two exclusive 5-year engagements with the Faculty of Pharmacy at a major Canadian university provide certified analytical testing capability, as well as extraction, isolation, and formulation facilities, and drug research and development expertise.

Quick facts: Xphyto Therapeutics Corp.

Price: 1.26 CAD

CSE:XPHY
Market: CSE
Market Cap: $59.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Xphyto Therapeutics Corp. named herein, including the promotion by the Company of Xphyto Therapeutics Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks start slow but Nextleaf picks up steam on...

Cannabis stocks had a slow start to Monday, with shares broadly flat across US and Canadian markets.  The North American Marijuana Index was down 0.8% at 189.9 points. Elsewhere, the OTCQX Cannabis Index inched up 0.1% at 687.5 points. Buds...

on 9/9/19

2 min read